AlanSCrossMD

PubMed

• 45 citations
  The Diversity of Lipopolysaccharide (O) and Capsular Polysaccharide (K) Antigens of Invasive Klebsiella pneumoniae in a Multi-Country Collection.
  Myeongjin Choi, Nicolas Hegerle, Joseph Nkeze, Shaichi Sen, Sanchita Jamindar
  Frontiers in Microbiology. 2020-06-12
• 53 citations
  Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa.
  Nicolas Hegerle, Myeongjin Choi, James Sinclair, Mohammed N. Amin, Morgane Ollivault-Shiflett
  Plos One. 2018-09-06
• 38 citations
  Progress towards the development of Klebsiella vaccines.
  Myeongjin Choi, Sharon M. Tennant, Raphael Simon, Alan S. Cross
  Expert Review of Vaccines. 2019-06-28

Journal Articles

• The NEU1-selective sialidase inhibitor, C9-butyl-amide-DANA, blocks sialidase activity and NEU1-mediated bioactivities in human lung in vitro and murine lung in vivo  
  Hyun SW,Liu A, Liu Z, Cross AS, Verceles AC, Magesh S, Kommalla Y, Ando H, Luzina IG, Atamas SP, Piepenbrink KH, Sundberg EJ, Guang W, Ishida H, Lillehoj EPand Goldblu..., Glycobiology, 1/1/2016
• Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding  
  Nita-Lazar M, Banerjee A, Feng C, Amin MN, Frieman MB, Chen WH, Cross AS, Wang L-X, Vasta GR, Molecular Immunology, 1/1/2015
• Intestinal dysbiosis following cholestasis is prevented by active immunization with a detoxified endotoxin vaccine  
  Alaish SM, Mongodin, Cross AS, J. Bacteriology and Mycology, 1/1/2015
• Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by vaccine-primed and costimulated autologous T-Cells  
  Rapoport AP, Aqui NS, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang H-B, Weiss BM, Badros A, Yanovich S, Akpek G, Cross A, Mann D, Philip S, Kerr N, Brennan A, Z..., Clin Cancer Res, 1/1/2014
• Candidate genes for limiting cholestatic intestinal injury identified by gene expression profiling  
  Alaish SM, Timmons J, Smith A, Buzza M, Murphy E, Zhao A, Turner DJ, Shea-Donahue T, Nataro JP, Antalis T, Cross A, Dorsey SG, Physiological Reports, 1/1/2013
• Anti-endotoxin vaccines: Back to the future  
  Cross AS, Virulence, 1/1/2013
• Effect of mammalian arginase inhibitor 2(S)-Amino-6-boronohexanoic acid on Bacillus anthracis anthracis arginase  
  Tsai P, Cao G-L, Tomczuk B, Suzdak PD, Cross AS, Shapiro P, Rosen GM., Current Microbiology, 1/1/2012
• NEU1 and NEU3 sialidase activity expressed in human lung microvascular endothelia NEU1 restrains endothelial cell migration whereas NEU3 does not  
  Cross AS, Hyun SW, Miranda-Ribera A, Feng C, Liu A, Nguyen C, Zhang L, Luzina IG, Atamas SP, Twaddell WS, Guang W, Lillehoj EP, Puché AC, Huang W, Wang L-X, Passaniti ..., J Biolog Chem, 1/1/2012
• A novel IFN-gamma-stimulated ATF6/C/EBP-beta signaling pathway critical for the expression of DAPK 1 and induction of autophagy  
  Gade P, Ramachandran G, Maachani UB, Rizzo MA, Okada T, Prywes R, Cross AS, Mori K, Kalvakolanu DV, Proc Natl Acad Sci, 1/1/2012
• Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination based on hTERT and surviving following ASCT for myeloma  
  Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang H-B, Cai L, Janofsky S, Chew A, Akpek G, Badros A, Yanovich S, Tan M, Veloso E, Pasetti M, Cross A, Philip S, Murphy..., Blood, 1/1/2011
• The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax  
  Brenneman K, Doganay M, Akmal A, Goldman S, Galloway D, Mateczun A, Cross A, Baillie L., FEMS Immunol Microbiol, 1/1/2011
• Endogenous PMN sialidase activity exposes activation epitope on CD11b/CD18 which enhances its binding interaction with ICAM-1  
  Feng C, Zhang L, Almulki L, Faez S, Whitford M, Hafezi-Moghadam A, Cross AS, J. Leukoc. Biol., 1/1/2011
• LPS-induced cytokine production in human dendritic cells is regulated by sialidase activity  
  Stamatos NM, Carubelli I, van de Vlekkert D, Bonten EJ, Papini N, Feng C, Venerando B, d’Azzo A, Cross AS, Wang L-X, Gomatos PJ., J Leuk Biol, 1/1/2010
• Immunization with Pseudomonas aeruginosa pilin provides O-antigen-specific protection  
  Horzempa J, Held TK, Cross AS, Furst D, Qutyan M, Neeley AN, Castric P, Clinical and Vaccine Immunology, 1/1/2008
• Macrophage proinflammatory response to Francisella tularensis Live Vaccine Strain requires coordination of multiple signaling pathways  
  Cole LE, Santiago A, Barry E, Kang TJ, Shirey KA, Roberts ZJ, Elkins KL, Cross A, Vogel SN, J. Immunol, 1/1/2008
• Induction of IL-1beta by Bacillus anthracis spores and lethal toxin occurs through distinct signaling pathways with disparate functional consequences  
  Kang TJ, Basu S, Zhang L, Thomas K, Vogel S, Baillie L, Cross A., Eur J Immunol, 1/1/2008
• Intranasal administration of a detoxified endotoxin vaccine protects against heterologous Gram-negative bacillary pneumonia  
  Chen WH, Kang TJ, Bhattacharjee AK, Cross AS, Innate Immunity, 1/1/2008
• Commentary: What is a virulence factor?  
  Cross AS, Crit Care, 1/1/2008
• Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant rec...  
  Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H, Kuypers J, Kim H, Gnann J, Whitley R and NIAID Collaborative Antiviral Study Group, Clin Infect Dis, 1/1/2007
• From rabbits to man: The contributions of Dr TE Woodward to tularemia research  
  Cross AS, Calia F, Edelman R., Clin Infect Dis, 1/1/2007
• The protective role of B anthracis exosporium in macrophage-mediated killing by nitric oxide  
  Weaver J, Kang TJ, Raines KW, Cao G-L, Hibbs S, Tsai P, Baillie L, Rosen G Cross AS, Infect Immun, 1/1/2007
• Recombinant exosporium protein BclA of Bacillus anthracis effective as a booster for mice primed with suboptimal amounts of protective antigen  
  Brahmbhatt TN, Darnell SC, Carvalho HM, Sanz P, Kang TJ, Bull RL, Rasmussen SB, Cross AS, O’Brien AD., Infect Immun, 1/1/2007
• From therapy to experimental model: A hundred years of endotoxin administration to human subjects  
  Bahador M, Cross AS, J. Endotox. Res, 1/1/2007
• Cellulitis in a patient with leukemia  
  Polk C, Forrest G, Cross A, Clin Infect Dis., 1/1/2007
• Development of an opsonin inhibition assay for evaluation of complex polysaccharide protective epitopes  
  McNeely T, Luo S, Manger W, Herber W, Schofield T, Tan C, Newman K, Sadoff J, Donnelly J, Cross A., Vaccine, 1/1/2006
• Join now to see all

Books/Book Chapters

• Endotoxins: Structure, function and recognition 
  Chapter: Development of an anti-endotoxin vaccine for sepsis 
  Page 285.0 - 302.0Cross ASEditors: X. Wang and P. Quinn.Subcellular Biochemistry2010
• New Generation Vaccines 
  Chapter: Tularemia Vaccines 
  Page 864.0 - 870.0Cross AS, Barry EMEditors: Levine MM.Informa Healthcare, New York, London2010
• Infectious Diseases 
  Chapter: Fever of Unknown Origin 
  Page 688.0 - 695.0Nguyen C and Cross ASEditors: Cohen J and Powderley WG.Elsevier2010
• Managing Infections in Patients with Hematological Malignancies 
  Chapter: Immunization of the immunocompromised hosts 
  Cross ASEditors: Kleinberg M.Humana Press2010
• New Generation Vaccines 
  Chapter: Adjuvants for the Future 
  Page 250.0 - 262.0Kenney RT, Cross ASEditors: Levine MM.Informa Healthcare, New York, LondonEdition 4th,2010
• Anaesthesia, Pain, Intensive Care and Emergency 
  Chapter: Chapter 44: Combination therapy for sepsis: the wave of the future or too complex to consider? 
  Opal SM, Cross ASEditors: A. Gullo.Springer2005
• Sepsis 
  Chapter: Vaccines against Bacterial Endotoxin 
  Bhattacharjee AK, Cross AS, and Opal SMEditors: J-L Vincent, J. Carlet and S. Opal.Kluwer Academic Publishers, Norwell, MA2002
• Molecular Medical Microbiology 
  Chapter: Interactions with the Compromised Host 
  Cross AS, Opal SMEditors: M. Sussman.Academic Press2001
• New Generation Vaccines 
  Chapter: Vaccines against Klebsiella, Pseudomonas and Septicemic E. coli Infections 
  Page 931.0 - 943.0Cross AS and Cryz Jr SJEditors: Woodrow GCand Levine MM.Marcel Dekker, Inc., New York and Basel1997
• Novel Therapeutic Strategies in the Treatment of Sepsis 
  Chapter: New Trends in Escherichia coli 0111: B4 J5 Mutant (Rc Chemotype) Vaccine Development for Use in Gram-negative Bacillary Sepsis 
  Page 1.0 - 12.0Bhattacharjee AK, Cross AS, Opal SH, Warren HS, Sadoff JCEditors: Morrison DC & Ryan JL.Marcel Dekker, Inc, New York1995
• Current Opinions in Infectious Diseases 
  Chapter: Endotoxin: It's Role in Gram-Negative Bacterial Infection 
  Page 156.0 - 163.0Cross AS and Opal SMEditors: D. Stevens.Current Science, Ltd., London, UK1995
• Immunobiology of Proteins and Peptides VIII 
  Chapter: IVIGs to Prevent and Treat Infectious Diseases 
  Page 123.0 - 130.0Editors: ME Atassi and GS Bixler, Jr..Plenum Press, New York1995
• Advances in the Treatment of Radiation Injuries 
  Chapter: Selection of Bacteria for Animal Models of Sepsis, from the Second Consensus Development Conference on the Treatment of Radiation Injuries (14-17 April 1993) 
  Cross AS, Sadoff J, Gemski P, Opal SEditors: T. MacVittie, J.F. Weiss, D.Pergamon, Elsevier Science1995
• Mediators of Sepsis 
  Chapter: Interaction of Bactericidal-Permeability Increasing Protein with Lipopolysaccharide and Experience in Animal Models of Gram-Negative Infections 
  Opal SM, Marra MN, Cross ASEditors: Ghanassia.1994
• Pseudomonas aeruginosa as an Opportunistic Pathogen. 
  Chapter: Local and Disseminated Diseases Caused by Pseudomonas aeruginosa. 
  Page 223.0 - 244.0Artenstein AW, Cross ASEditors: M Campa, M Bendinelli, and H Friedman.Plenum Press, New York, London1993
• Intravenous Immunoglobulin Therapy. 
  Chapter: The Use of Intravenous Immunoglobulin in Bacterial Infections 
  Page 139.0 - 166.0Cross ASEditors: PL Yap.Churchill-Livingstone, Edinburgh, London, Madrid, Melbourne, New York and Tokyo1992
• Vaccines and Immunotherapy 
  Chapter: Klebsiella 
  Page 178.0 - 185.0Cross AEditors: J Jr.Pergamon Press, New York, Oxford, Beijing, Frankfurt, Sao Paolo, Sydney, Tokyo, Toronto1991
• Ullmann's Encyclopedia of Industrial Chemistry 
  Chapter: Immunotherapy & Vaccines 
  Page 92.0 - 104.0Cross ASEditors: J Jr.VCH Verlagsgesellschaft, Weinheim (FRG)Edition 5th,1991
• Vaccines and Immunotherapy 
  Chapter: Immunotherapy 
  Page 91.0 - 119.0Cross ASEditors: Cryz SJ Jr.VCH Verlagsgesellschaft, Weinheim1991
• Contemporary Issues in Infectious Diseases: Treatment of Serious Infections in the 1990s 
  Chapter: Immunotherapy of Gram-Negative Bacillary Sepsis: A Process-Oriented Approach 
  Page 72.0 - 92.0Cross AS, Sadoff J, Opal S, Cryz SJ JrEditors: Sande MA, Root RK.Churchill Livingstone, New York, Edinburgh, London, Melbourne, Tokyo1991
• The Physiological and Pathological Effects of Cytokines. 
  Chapter: Non-Lethal and Lethal Production of Cytokines (TNF and IL6) in Response to Bacterial LPS 
  Page 147.0 - 152.0Kelly N and Cross ASEditors: C.A. Dinarello, M.C. Powanda, J.J. Oppenheim.Wiley-Liss, New York, Chichester, Brisbane, Toronto, Singapore1990
• Current Topics in Microbiology and Immunology 
  Chapter: Cross A: "Biologic Consequences of Bacterial Encapsulation" 
  Page 87.0 - 96.0Editors: K. Jann and B. Jann.Springer-Verlag,Berlin, Heidelberg, New York, London, Paris, Tokyo, Hong Kong1990
• Handbook of Clinical Neurology 
  Chapter: Neurologic Sequelae to Pertussis, Diphtheria and Tetanus and Immunization 
  Page 227.0 - 251.0Cross AS and Sadoff JCEditors: A.A. Harris.Elsevier Science Publishers B.V., Amsterdam, New York1988
• Bacterial Vaccines 
  Chapter: A Passive Immunization with Monoclonal Antibodies Against E. coli and P. aeruginosa 
  Page 507.0 - 519.0Sadoff JC, Wright CD, Kaufman B, Futrovsky S, Sidberry H, Collins H, Kim K and Cross ASEditors: JB Robbins, RS Schneerson, D Klein, J Sadoff, MC Hardegree.Praeger, N.Y., Westport, CT, London1987
• Current Clinical Topics in Infectious Diseases 
  Chapter: Infections Associated with Hemodialysis and Chronic Peritoneal Dialysis 
  Page 124.0 - 145.0Steigbigel RT, Cross ASEditors: Remington and Swartz.1984
• Join now to see all

Abstracts/Posters

• Structural elucidation of Gram-negative bacterial endotoxins by tandem mass spectrometry
  Khan MM, Oyler BL, Gregg KA, Ernst RK, Cross AS, Goodlett DR, Amercian Society for Mass Spectroscopy, Annual Meeting, San Antonio, TX, 1/1/2016
• Genetic variation regulates the expression of the tight junction proteins at baseline and following common bile duct ligation
  Smith A, Timmons J, Murphy E, Zhao A, Cross A, Alaish SM, JACS, Pediatric Surgery I, Surgical Forum, American College of Surgeons Clinical Congress, Chicago, IL, 1/1/2012
• Genetic variation in the intestinal barrier in a cholestasis model.
  Alaish SM, Timmons J, Zhao A, Dorsey SG, Shea-Donahue T, Fasano A, Nataro JP, Cross A, Mucosal Biology: A fine balance between tolerance and immunity, Keystone Symposia, Vancouver, British Colombia, Canada, 1/1/2011
• Expression and secretion of galectins in the murine lung is modulated during influenza and pneumococcal infection.
  Nita-Lazar M, Pasek M, Chen W, Feng C, Cross A, Rabinovich G, Vasta G, Society for Glycobiology Annual Meeting, Seattle, WA, 1/1/2011
• Expression and secretion of galectins in the murine lung is modulated during influenza and pneumococcal infection
  Nita-Lazar M, Pasek M, Chen W, Feng C, Cross A, Rabinovich G, Vasta G, Society for Glycobiology Annual Meeting, Seattle, WA, 1/1/2011
• Novel peptide antagonist therapy for superantigen-induced lethal shock.
  Cross A, Ramachandran G, Whitford M, Kaempfer R, Arad G., National Meeting of the Regional Centers of Excellence, Las Vegas, NEV, 1/1/2010
• Intestinal permeability and bacterial translocation are modulated by the genetic background of the host”
  Alaish S, Shea-Donohue T, Cross AS, Nataro J., Digestive Diseases Week, Gastroenterology, AGA, Digestive Disease Week, Chicago, IL, 1/1/2009
• Was the Boston tea party a mistake? Tea promotes the killing of B. anthracis via a complex pro-oxidant mechanism
  Huwar T, Baillie L, Rosen G, Basu S, Cross AS, Bacillus-ACT, Santa Fe, NM, 1/1/2009
• Schedule dependent effects of adoptively transferred autologous T cells after AutoSCT for myeloma: accelerated immune recovery is associated with improved event-free s...
  Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang H-B, Janofsky S, Storek J, Chew A, Veloso E, Akpek G, Yanovich S, Tan MT, Wu Y, Cross A, Philip S, Murphy H, Bhagat ..., American Soc Hematolo, 1/1/2009
• Early interactions of B. anthracis and F. tularensis in mice and humans
  Cross AS, Society for Risk Analysis, National Meeting, Baltimore, MD, 1/1/2009
• Cellular and Humoral Immune Responses of Elderly Adults Who Received a High-dose or Standard-dose Influenza Vaccine
  Chen WH, Bowen S, Cross AS, Edelman R, Hayes M, Lim Y, Reymann M, Ruslanova I, Wu S, Sztein MB, Pasetti MF, 11th Vaccine NFID Meeting, Baltimore, MD, 1/1/2008
• Occult infections in critically ill trauma patients.
  Johnson SB, Lissauer M, Field C, Cross AS, Keating W, Scalea TM, Surgical Infection Society, 1/1/2007
• A monoclonal antibody that neutralizes lethal toxin mediates the killing of B. anthracis by murine macrophages.
  Basu S, Kang TJ, Langermann S, Riddle V, Lowy I, Cross AS, BACT, Oslo, Norway, 1/1/2007
• A lethal-toxin-neutralizing monoclonal antibody mediates the killing of B. anthracis
  Basu S, Kang TJ, Langermann S, Riddle V, Lowy I, Mann DL, Cross A, ICAAC, Chicago, IL, 1/1/2007
• Toll-like receptor pathway gene expression: sepsis or uninfected systemic inflammatory response syndrome (SIRS)?
  Lissauer M, Johnson S, Bochicchio G, Field C, Cross A, Hasday J, Scalea T, Whitford C, Nussbaumer W, Moore R, Soc. Critical Care Med., 1/1/2006
• Role of Bacillus anthracis spore structures in TLR-mediated cytokine responses
  Basu S, Chen WH, Fenton MJ, Baillie L, Hibbs S, Kang TJ, Cross AS, ASM Conference on Biodefense, Washington, DC., 1/1/2006
• Role of STAT1 in the regulation of lipopolysaccharide-induced interleukin-1beta expression.
  Joshi VD, Kalvakolanu DV, Chen W, Basu S, Zhang L, Vogel S, Cross AS, Keystone Conference on Innate Immunity, Banff, CANADA, 1/1/2006
• Gene expression profiles differentiate between SIRS and early sepsis.
  Johnson SB, Lissauer M, Bochicchio G, Moore R, Cross A, Scalea T, 126th Annual Meeting of the American Surgical Association, Boston, MA, 1/1/2006
• Synergistic TLR signaling is required for optimal antibody response to an endotoxin-based sepsis vaccine.
  Chen WH, Basu S., Bhattacharjee AK and Cross AS., National Foundation for Infectious Diseases, 9th Annual Conference on Vaccine Research, 1/1/2006
• Spreading the neus: the role of sialic acid modulation in neutrophil function
  Cross AS, Goldblum SE, Stamatos NM., Trends in Glycoscience and Glycotechnology, 1/1/2006
• MyD88-dependent and –independent pathways are required for host defense against B. anthracis infection.
  Kang TJ, Basu S, Zhang L, Thomas KE, Vogel SN, Baillie LW, Cross AS., Society of Leukocyte Biology/International Endotoxin and Innate Immunity Society, San Antonio, TX, 1/1/2006
• Toll-like receptor pathway gene expression: sepsis or uninfected systemic inflammatory response syndrome?
  Lissauer M, Johnson S, Bochicchio G, Field C, Cross A, Hasday J, Scalea T, Whitford C, Nussbaumer W, Moore R, Society for Critical Care Medicine, 1/1/2006
• The Immunological Synapse is down-regulated in SIRS patients prior to sepsis.
  Johnson SB, Lissauer M, Whiteford C, Bochicchio GV, Moore R, Cross AS, Garrett J, Scalea T, Surgical Infection Society, 1/1/2006
• Inflammatory biomarkers in the systemic inflammatory response syndrome (SIRS): Are there differences in patients that become septic?
  Johnson SB, Cross A, Hasday J, Bochicchio G, Shanholtz C, Towns M, Moore R, Soc. Of Critical Care Medicine, Orlando, FL, 1/1/2005
• Expression of sialyltransferase activity on intact human neutrophils
  Rifat S, Zhou J, Mann D, Stamatos NM, Fulton A, Goldblum SE, Cross AS, Keystone Conference: Leukocyte Trafficking, Taos, NM, 1/1/2005
• Join now to see all

Lectures

• Antibiotic prophylaxis for patients with orthopedic appliances undergoing dental procedures 
  1/1/2012
• Sialyl residues modulate LPS-mediated signaling through the Toll-like receptor 4 complex 
  Lucca, Italy - 1/1/2011
• ICE-ing anthrax: the role of caspase-1 in the innate immune response to B. anthracis 
  1/1/2006
• A detoxified endotoxin complex vaccine for the active prophylaxis or passive treatment of sepsis 
  Baltimore, MD - 1/1/1999
• Diagnosis and management of infections diseases in the non-HIV compromised host 
  Brooke Army Medical Center, San Antonio, Texas - 1/1/1999
• Immune Modulation in the Adjunctive Therapy of Sepsis 
  Brooke Army Medical Center - 1/1/1999
• New Directions in the Treatment of Febrile Neutropenia 
  Cancer Institute at Washington Hospital Center, Washington, D.C. - 1/1/1999
• Current status of anti-endotoxin antibodies in the therapy of sepsis 
  Snowbird, Utah - 1/1/1998
• Outpatient management of febrile neutropenia 
  University of Texas Southwestern Medical Center - 1/1/1998
• A new generation of anti-endotoxin antibodies: new approaches to a vexing problem 
  Rotterdam, the Netherlands - 1/1/1998
• Passive immunotherapy for the treatment of Gram-negative bacterial infection: future prospects 
  Berne, Switzerland - 1/1/1998
• Infections in the Non-HIV-infected Compromised Host 
  Army Section, Reston, VA - 1/1/1998
• Immunotherapeutic approaches to the treatment of sepsis 
  University of Massachusetts Medical Center, Worcester, MA - 1/1/1997
• Treatment of sepsis with anti-endotoxin and type-specific immunoglobulins 
  Munich, Germany - 1/1/1997
• Animal Models Made Easy 
  Washington, D.C. - 1/1/1997
• Role of Sialidase in Neutrophil Trafficking 
  Washington, D. C. - 1/1/1997
• Gram-negative bacterial sepsis: The enduring conundrum 
  Toronto, Canada - 1/1/1997
• Prevention of sepsis 
  Snowbird, Utah - 1/1/1996
• Critical ICU Pathogens 
  New Orleans, L - 1/1/1996
• Role of Passive Immunization in the Prevention of Infection in the ICU 
  New Orleans, LA - 1/1/1996
• Development of Anti-endotoxin Vaccine 
  Center for Biologics Evaluation and Research, Bethesda, MD - 1/1/1996
• Septic Shock 
  Harbor Hospital Center, Baltimore, MD - 1/1/1996
• Development of anti-endotoxin vaccine for sepsis 
  University of Maryland - 1/1/1996
• The development of an anti-endotoxin (J5) vaccine for the active and passive treatment of sepsis 
  Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bet - 1/1/1996
• Development of an Anti-Endotoxin Subunit Vaccine for Human Use 
  Woods Hole, MA - 1/1/1996
• Join now to see all

Other

• Taking exception: We need a broad approach to confronting superbugs. 
  Cross A, Washington Post
  1/3./2016